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Dura mater graft-associated Creutzfeldt-Jakob disease (dCJD) can be divided into two subgroups that exhibit distinct
clinical and neuropathological features, with the majority represented by a non-plaque-type of dCJD (np-dCJD) and
the minority by a plaque-type of dCJD (p-dCJD). The two distinct phenotypes of dCJD had been considered to be
unrelated to the genotype (methionine, M or valine, V) at polymorphic codon 129 of the PRNP gene or type (type 1 or
type 2) of abnormal isoform of prion protein (PrPSc) in the brain, while these are major determinants of clinicopathological
phenotypes of sporadic CJD (sCJD). The reason for the existence of two distinct subgroups in dCJD had remained elusive.
Recent progress in research of the pathogenesis of dCJD has revealed that two distinct subgroups of dCJD are caused
by infection with different PrPSc strains from sCJD, i.e., np-dCJD caused by infection with sCJD-MM1/MV1, and p-dCJD
caused by infection with sCJD-VV2 or -MV2. These studies have also revealed previously unrecognized problems as
follows: (i) the numbers of p-dCJD patients may increase in the future, (ii) the potential risks of secondary infection from
dCJD, particularly from p-dCJD, may be considerable, and (iii) the effectiveness of the current PrPSc decontamination
procedures against the PrPSc from p-dCJD is uncertain. To prevent secondary infection from p-dCJD, the establishment
of effective decontamination procedures is an urgent issue. In this review, we summarize the past and future problems
surrounding dCJD.
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Dura mater grafts used to repair the dural defects at neuro-
surgery can cause fatal disease years to decades later. The
tragedy of dura mater graft-associated Creutzfeldt-Jakob
disease (dCJD) was considered to be nearly over. However,
recent progress in research of the pathogenesis of dCJD
has revealed previously unrecognized problems. In this re-
view, we summarize the past and future problems sur-
rounding dCJD.
Creutzfeldt-Jakob disease (CJD) is a lethal transmis-
sible neurodegenerative disease. The central event in the
pathogenesis of CJD is a conformational change of the
normal cellular isoform of prion protein (PrPC) into an
abnormal infectious isoform of prion protein (PrPSc) [1].
The conformational change of PrPC can occur due to* Correspondence: kitamoto@med.tohoku.ac.jp
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unless otherwise stated.either one of three causes: spontaneous conversion in
sporadic CJD (sCJD), mutations in the PRNP gene in
genetic CJD, or infection with PrPSc in iatrogenic CJD
and variant CJD.
One of the most frequent sources of iatrogenic PrPSc
infection is dura mater grafts obtained from human
cadavers undiagnosed as CJD. The sum of dCJD (228
cases) and growth hormone-associated CJD (226 cases)
accounts for 97% of total iatrogenic CJD cases [2]. A sin-
gle brand of dura mater graft, Lyodura®, was used for all
the dCJD cases in whom the brand name was identified.
Although the causative dura mater grafts were manufac-
tured by a German company, 62% (142 cases) of total
dCJD cases have been found in Japan [2,3]. Persistent ef-
forts of a Japanese CJD surveillance team have clarified
the outline of dCJD outbreaks. The onset of Japanese
dCJD patients peaked in the late 1990s, and most of the
patients had received the grafts during 1983–1987, while
as many as 100,000 persons received the Lyodura® graftsral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Clinicopathological features of the two subgroups of
dCJD. The patients with dCJD can be divided into two subgroups,
with the majority represented by a non-plaque-type of dCJD
(np-dCJD) and the minority by a plaque-type of dCJD (p-dCJD)
[11,12]. Neuropathological hallmark of p-dCJD is widespread PrPSc
amyloid plaques, while np-dCJD shows diffuse synaptic-type
PrPSc deposition.
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this elaborate survey, a puzzling mystery about dCJD
emerged.
A mystery about dCJD
There is growing evidence that dCJD can be divided into
two subgroups that exhibit distinct clinical and neuro-
pathological phenotypes, with the majority (68%) repre-
sented by a non-plaque-type of dCJD (np-dCJD) and
the minority (32%) by a plaque-type of dCJD (p-dCJD)
(Figure 1) [6-12]. The clinicopathological features ofFigure 2 Two major determinants of the phenotypic heterogeneity o
PrPSc in the brain. Types 1 and 2 PrPSc are cleaved by proteinase K at differ
analysis, types 1 and 2 PrPSc are distinguishable by the size of the proteina
respectively) [17].np-dCJD are identical to those of classical sCJD, whereas
p-dCJD is characterized by (i) ataxic gait as an initial
symptom, (ii) slow progression of neurological symptoms,
(iii) absence or late occurrence of periodic sharp-wave
complexes (PSWC) on electroencephalogram (EEG), and
(iv) widespread PrPSc amyloid plaques in the brain
[11-16]. There is no significant difference in gender com-
position, site of graft, age at grafting, and year of grafting
between the two subgroups [11,12].
sCJD also shows wide phenotypic heterogeneity, and
its clinicopathological phenotypes are determined by the
genotype at polymorphic codon 129 of the PRNP gene
and type of PrPSc in the brain (Figure 2) [17,18]. The
codon 129 of the PRNP gene shows methionine (M)/val-
ine (V) polymorphism. Two types of PrPSc (type 1 and
type 2) are distinguishable according to the size of
the proteinase K-resistant core of unglycosylated PrPSc
(21 and 19 kDa, respectively), reflecting differences in
the proteinase K-cleavage site (at residues 82 and 97, re-
spectively) [19]. On the other hand, the two distinct phe-
notypes of dCJD had been considered to be unrelated to
their PRNP genotype or type of PrPSc in the brain [11].
In Japan, almost all dCJD patients had the same geno-
type, i.e., homozygous for methionine at codon 129
(129 M/M), except two heterozygotes [2], and the type
of PrPSc in their brains had been reported as type 1
[6,10,11]. The reason for the existence of two distinct
subgroups in dCJD had remained elusive.
Solving the mystery
In 2003, an unusual p-dCJD case was reported [9]. This
patient showed the accumulation of unusual PrPSc with
intermediate electrophoretic mobility between types 1
and 2 PrPSc. Then, we reevaluated the biochemical
properties of PrPSc in the two subgroups of dCJD and
found that the size of PrPSc from p-dCJD was invariably
smaller than that of type 1 PrPSc from np-dCJDf sCJD. (a) The PRNP genotype at polymorphic codon 129. (b) Type of
ent sites (at residues 82 and 97, respectively) [19]. (c) In western blot
se K-resistant core of the unglycosylated PrPSc (21 and 19 kDa,
Figure 3 Distinct biochemical properties of PrPSc in the two
subgroups of dCJD. The intermediate-sized PrPSc in p-dCJD, desig-
nated as type i PrPSc, was smaller than type 1 PrPSc in np-dCJD [20].
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nated as type i PrPSc.
To resolve the mystery of the existence of two distinct
subgroups in dCJD, we hypothesized that they might be
caused by infection with different PrPSc strains from dis-
tinct sCJD subgroups. According to the PRNP genotype
and type of PrPSc in the brain, sCJD is classified into six
subgroups (MM1, MV1, VV1, MM2, MV2, or VV2)
[17]. MM1 and MV1, which are the predominant sub-
groups in sCJD, show the same clinicopathological
features. Meanwhile, MM2 can be divided into three
subgroups based on histopathological criteria (MM2T,
thalamic form showing characteristic atrophy of thal-
amic and inferior olivary nuclei; MM2C, cortical form
showing a predominant cortical pathology; or MM2T +
C, mixed form) [17,21]. In addition, MV2 is also di-
vided into three subgroups based on histopathologicalTable 1 Transmission of dCJD or sCJD to PrP-humanized mice
Inoculum (ID)
Tg + Ki-Hu129 M/M
(9.8×)c
np-dCJD (GF) 161 ± 5 (5/5)
np-dCJD (TC) 208 ± 2 (5/5)
p-dCJD (KR) 420 ± 10 (5/5)
p-dCJD (KD) 398 ± 10 (5/5)
sCJD-MM1 175 ± 4 (9/9)
sCJD-VV2 505 ± 14 (5/5)
sCJD-MV2K N.D.
sCJD-MV2K+C N.D.
129 M/M mouse-passaged sCJD-VV2 N.D.
an, number of mice positive for PrP accumulation in the immunohistochemical anal
Ki-Hu129M/M, knock-in mice expressing human PrP with the 129 M/M genotype; K
Tg + Ki-Hu129M/M, Ki-Hu129M/M crossed with transgenic mice overexpressing hum
dN.D., not done.criteria (MV2K showing kuru type PrPSc amyloid plaques,
MV2C showing a predominant cortical pathology, or
MV2K + C showing mixed histopathology) [17,18]. The
clinicopathological features of np-dCJD, such as short dur-
ation of illness, PSWC on EEG, or diffuse synaptic-type
PrPSc deposition in the brain, are identical to those of
sCJD-MM1/MV1. In contrast, the clinicopathological fea-
tures of p-dCJD, such as ataxic gait as an initial symptom,
slow progression of neurological symptoms, absence or
late occurrence of PSWC on EEG, or formation of PrPSc
plaques in the brain, are similar to those of sCJD-VV2,
−MV2K, or -MV2K + C. These similarities raised the pos-
sibility that np-dCJD might be caused by infection with
sCJD-MM1/MV1, whereas p-dCJD might be caused by in-
fection with sCJD-VV2, −MV2K, or -MV2K + C.
To test this possibility, we examined the transmission
properties of the dCJD and sCJD subgroups using
humanized mice carrying human PrP with either the
129 M/M or V/V genotype [20,22,23]. In these transmis-
sion experiments, p-dCJD and sCJD-VV2, −MV2K, or
-MV2K + C were identical in the transmissibility to the
PrP-humanized mice (Table 1, Figure 4a) and in the
neuropathological and biochemical features in the inocu-
lated mice (Figure 4b, c). By contrast, np-dCJD showed
the same transmission properties as sCJD-MM1. In
particular, the 129 M/M mice inoculated with sCJD-
VV2, −MV2K, or -MV2K + C material showed wide-
spread PrPSc plaques and type i PrPSc accumulation
similar to the p-dCJD patients, whereas the 129 M/M
mice inoculated with sCJD-MM1 material showed dif-
fuse synaptic-type PrPSc deposition and type 1 PrPSc ac-
cumulation similar to the np-dCJD patients. Thus, these
animal models support the hypothesis that the origin of
np-dCJD is sCJD-MM1/MV1 and that of p-dCJD isIncubation period in days ± SEM (n/n0)a





685 ± 51 (5/5) 259 ± 6 (6/6)
447 ± 51 (6/6) 317 ± 8 (11/11)
467 ± 24 (8/8) 774 ± 32 (6/6)
633 ± 49 (6/6) 302 ± 9 (7/7)
638 ± 57 (4/4) 329 ± 3 (4/4)
600 ± 22 (6/6) 332 ± 15 (4/4)
685 ± 17 (6/6) 309 ± 3 (7/7)
ysis; n0, number of inoculated mice.
i-Hu129V/V, knock-in mice expressing human PrP with the 129 V/V genotype;
an PrP with the 129 M genotype.
Figure 4 Transmission of dCJD or sCJD to humanized mice carrying human PrP with either the 129 M/M or 129 V/V genotype.
(a) p-dCJD and sCJD-VV2, −MV2K, or -MV2K + C were identical in the transmissibility to the PrP-humanized mice. (b) Immunohistochemical
analysis of PrPSc in the mouse brain revealed that p-dCJD and sCJD-VV2, −MV2K, or -MV2K + C were indistinguishable with regard to the
neuropathological phenotypes in the inoculated mice. G, gray matter; W, white matter. (c) Westernblot analysis of PrPSc in the mouse brain
showed that p-dCJD and sCJD-VV2, −MV2K, or -MV2K + C were also indistinguishable with regard to the biochemical properties of PrPSc in the
inoculated mice. 129 M/M, knock-in mice expressing human PrP with the 129 M/M genotype; 129 V/V, knock-in mice expressing human PrP
with the 129 V/V genotype.
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rate of p-dCJD (32%) among total dCJD is close to the
sum total of the incidence of sCJD-VV2 (15%), −MV2K
(8%), and -MV2K + C (3%) [18].
Molecular basis of the generation of two distinct
subgroups in dCJD
At the molecular level, np-dCJD contains type 1 PrPSc
with the codon 129 M genotype (denoted as M1 PrPSc),whereas p-dCJD contains type i PrPSc with the codon
129 M genotype (Mi PrPSc) (Table 2). Meanwhile, sCJD-
MM1/MV1 contains M1 PrPSc, and sCJD-VV2 contains
type 2 PrPSc with the codon 129 V genotype (V2 PrPSc).
Recently, we found that sCJD-MV2K contains Mi PrPSc
and V2 PrPSc, whereas sCJD-MV2K + C also contains
type 2 PrPSc with the codon 129 M genotype and cor-
tical pathology (M2C PrPSc) in addition to Mi PrPSc and
V2 PrPSc (Table 2) [23]. M2 PrPSc can be divided into
Table 2 Molecular classification of dCJD and sCJD
Classificationa Codon 129 genotype PrPSc type Transmission typeb Original PrPSc Existing PrPSc
np-dCJD M/M 1 M1 M1 M1
p-dCJD M/M i c V2 V2 d Mi
sCJD-MM1 M/M 1 M1 M1 M1
sCJD-VV2 V/V 2 V2 V2 V2
sCJD-MV2K M/V i + 2 V2 V2 Mi + V2
sCJD-MV2K+C M/V i + 2 V2 M2Ce + V2 M2C + Mi + V2
aAccording to Parchi, 1999 [17]; and Parchi, 2011 [18].
bAccording to Bishop, 2010 [24]; Kobayashi, 2007 [20]; and Kobayashi, 2013 [23].
cIntermediate type located between types 1 and 2 PrPSc.
dAlthough not only V2 PrPSc but also Mi PrPSc can cause p-dCJD if transmitted to the 129 M/M individuals, the primary origin of Mi PrPSc is V2 PrPSc (see text).
eM2 PrPSc can be divided into two subgroups based on histopathological phenotypes. M2C PrPSc causes a predominant cortical pathology, whereas M2T PrPSc
causes atrophy of thalamic and inferior olivery nuclei.
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M2C PrPSc causes a predominant cortical pathology in
sCJD-MM2C, −MV2C, or -MV2K + C, whereas M2T
PrPSc causes atrophy of thalamic and inferior olivery nu-
clei in sCJD-MM2T.
The generation of M1 PrPSc in np-dCJD is simply due
to the infection with M1 PrPSc from sCJD-MM1/MV1.
On the other hand, the generation of Mi PrPSc in
p-dCJD is rather complicated. Transmission of V2 PrPSc,
i.e., sCJD-VV2, to the 129 M/M mice generated Mi
PrPSc (Figure 4c) [20]. Similarly, transmission of Mi
PrPSc, i.e., p-dCJD, to the 129 M/M mice also generated
Mi PrPSc. Therefore, both V2 PrPSc and Mi PrPSc can
generate Mi PrPSc if transmitted to individuals with the
129 M/M genotype. Indeed, transmission of sCJD-
MV2K containing Mi PrPSc and V2 PrPSc to the 129 M/
M mice also generated Mi PrPSc (Figure 4c). Meanwhile,
sCJD-MV2K + C contains M2C PrPSc besides Mi PrPSc
and V2 PrPSc (Table 2). However, M2C PrPSc lacks or
has very low infectivity and does not affect the transmis-
sion properties of the coexisting PrPSc [23]. Therefore,
the transmission of sCJD-MV2K + C to the 129 M/M
mice can also result in the generation of Mi PrPSc
(Figure 4c). Taken together, Mi PrPSc in p-dCJD is gen-
erated by infection with Mi PrPSc and/or V2 PrPSc from
sCJD-VV2, −MV2K, or -MV2K + C. It is noteworthy
that Mi PrPSc can be observed in the 129 M/M mice in-
oculated with V2 PrPSc but not in sCJD patients with the
129 M/M genotype, suggesting that Mi PrPSc in sCJD-
MV2K or -MV2K + C is also generated by V2 PrPSc
seed-dependent conversion but not by spontaneous con-
version of the 129 M PrPC. Therefore, the primary origin
of Mi PrPSc is V2 PrPSc. This can account for the simi-
larities in transmission properties between Mi PrPSc and
V2 PrPSc. Thus, M1 PrPSc in np-dCJD and Mi PrPSc in
p-dCJD are completely different with regard to the
neuropathological phenotypes, biochemical features, and
transmission properties, reflecting their distinct PrPSc
origins. In contrast to M1 PrPSc, which is the mostcommon PrPSc observed in sCJD patients with the
129 M/M genotype, Mi PrPSc has never been observed
in sCJD patients with the 129 M/M genotype. Therefore,
the detection of Mi PrPSc can be sound evidence of iat-
rogenic infection in individuals with the 129 M/M geno-
type and would contribute to reliable surveillance of
iatrogenic cases such as p-dCJD.
To verify experimentally that Mi PrPSc originates from
V2 PrPSc and its transmission properties are identical to
those of the parental V2 PrPSc, we performed a modeling
study using PrP-humanized mice (Figure 5a) [25]. As
described above, the 129 M/M mice inoculated with
V2 PrPSc showed widespread PrPSc plaques and Mi PrPSc
accumulation in the brain as an experimental model of
p-dCJD. We then inoculated the Mi PrPSc from these mice
into other PrP-humanized mice with either the 129 M/M
or V/V genotype. This secondary passage revealed that the
transmission properties of the Mi PrPSc, i.e., 129 M/M
mouse-passaged sCJD-VV2, are identical to those of the
parental V2 PrPSc. In particular, although the incompati-
bility of the codon 129 genotypes between host and inocu-
lum usually results in a prolonged incubation period [20],
the 129 V/V mice inoculated with the Mi PrPSc showed a
shorter incubation period compared with the 129 M/M
mice (Table 1). Moreover, the altered neuropathological
phenotype and biochemical properties at the primary pas-
sage in the 129 M/M mice reverted to the original ones in
the secondary passage in the 129 V/V mice (Figure 5b, c).
Thus, this modeling study shows that (i) V2 PrPSc infec-
tion in a host with the incompatible codon 129 M/M
genotype generates an unusual PrPSc with altered con-
formational properties, i.e., Mi PrPSc, (ii) the emerging
Mi PrPSc retains the memory of the parental V2 PrPSc
within its conformational properties, and (iii) the parental
V2 PrPSc re-emerges and proliferates rapidly if the Mi
PrPSc is transmitted to the original host with the codon
129 V/V genotype. This phenomenon, designated as trace-
back, can be a useful tool to identify the origin of PrPSc in-
fection if atypical PrPSc emerges in the future [20,22,26].
Figure 5 Modeling of p-dCJD and traceback phenomenon.
(a) Schematic diagram of the modeling study. The 129 V/V mice
were highly susceptible to the 129 M/M mouse-passaged sCJD-VV2,
i.e., Mi PrPSc, despite their incompatible codon 129 genotypes.
Moreover, the altered neuropathological and biochemical pheno-
types in the primary passage in the 129 M/M mice reverted to the
original ones in the secondary passage in the 129 V/V mice. This is
because the origin of Mi PrPSc is V2 PrPSc. This phenomenon has
been designated as traceback [20,26]. (b) Immunohistochemical
analysis of PrPSc in the brains from the PrP-humanized mice infected
with the 129 M/M mouse-passaged sCJD-VV2. G, gray matter; W,
white matter. (c) Westernblot analysis of PrPSc in the brains from
the PrP-humanized mice infected with sCJD-VV2 or the 129 M/M
mouse-passaged sCJD-VV2. 129 M/M, knock-in mice expressing
human PrP with the 129 M/M genotype; 129 V/V, knock-in mice
expressing human PrP with the 129 V/V genotype.
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Our transmission studies resolved the complicated patho-
genesis of dCJD. However, they have also revealed several
issues surrounding dCJD that need to be addressed in the
future.
First, the numbers of p-dCJD patients may increase in
the future. The experimental p-dCJD model, i.e., the
129 M/M mice inoculated with Mi PrPSc and/or V2
PrPSc from sCJD-VV2, −MV2K, or -MV2K + C, showed
a longer incubation period compared with the np-dCJD
model, i.e., the 129 M/M mice inoculated with M1 PrPSc
from sCJD-MM1 (Table 1). This raises the concern that
additional p-dCJD patients, who are presenting still at
the subclinical stage, may emerge after a longer incuba-
tion period in the future. Although the numbers of
patients with newly developed dCJD have dropped
off, continuous surveillance will be required to find
remaining p-dCJD cases.
Second, the potential risks of secondary infection from
dCJD, particularly from p-dCJD, may be considerable.
As described above, the transmission studies raise a con-
cern about the existence of subclinical p-dCJD patients.
dCJD patients may undergo more than one neurosurgi-
cal operation due to their underlying diseases (the pri-
mary disease for which the neurosurgery was performed)
[4]. In addition, p-dCJD patients may be more frequently
autopsied because the clinical features of p-dCJD are
atypical compared with those of classical sCJD [11].
These facts suggest that there may be considerable risk
of secondary infection from p-dCJD patients. Individuals
with the 129 V/V genotype may be more vulnerable to
the infection with Mi PrPSc from p-dCJD, as suggested
by the fact that the 129 V/V mice were highly suscep-
tible to Mi PrPSc in the transmission study (Table 1).
Additionally, 129 M/M individuals may be also affected
after a prolonged incubation period, as suggested by the
high attack rate (100%) of the 129 M/M mice inoculated
with Mi PrPSc. Therefore, secondary infection from
p-dCJD can occur regardless of the codon 129 genotype.
Comprehensive analysis of the distribution of PrPSc in
the peripheral tissues of p-dCJD patients will be also
required to assess the potential risks of secondary
infection.
Finally, the efficacy of the current PrPSc decontamin-
ation procedures against Mi PrPSc needs to be tested in
the future. Mi PrPSc in p-dCJD and M1 PrPSc in np-
dCJD differ in the sizes of the proteinase K-resistant
core, suggesting their conformational differences. More-
over, their parental PrPSc strains are also different.
Different PrPSc strains can show different thermostability
[27,28] and different susceptibility to the decontamin-
ation procedures [29]. To prevent the spread of secondary
infection from dCJD patients to medical workers or other
patients, adequate decontamination and disinfection of
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sential. However, the current PrPSc decontamination pro-
cedures were developed using scrapie isolates and tested
using CJD isolates other than p-dCJD [30-32]. Therefore,
further studies using Mi PrPSc will be needed to assess the
effectiveness of the current procedures. For this purpose,
sensitive detection systems for Mi PrPSc are also pre-
requisite to evaluating quantitatively the reduction of in-
fectivity after the decontamination procedures. Real-time
quaking-induced conversion [33,34], protein misfolding
cyclic amplification [35-39], or transgenic mice overex-
pressing human PrP with the 129 V genotype [20] might
be useful to detect the reduced infectivity of Mi PrPSc at
high sensitivity. Using such sensitive detection systems,
effective decontamination procedures for Mi PrPSc can be
established in the future.
Concluding remarks
Recent progress in the study of the pathogenesis of
dCJD has revealed that the two distinct subgroups of
dCJD are caused by infection with different PrPSc strains
of sCJD, i.e., np-dCJD caused by M1 PrPSc from sCJD-
MM1/MV1 and p-dCJD caused by Mi PrPSc and/or V2
PrPSc from sCJD-VV2, −MV2K, or -MV2K + C. Studies
have also revealed previously unrecognized problems
such as the considerable risks of secondary infection
from dCJD, particularly from p-dCJD. To prevent sec-
ondary infection from p-dCJD, the effectiveness of the
current decontamination procedures should be tested
urgently using sensitive Mi PrPSc detection systems.
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